CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 42 enrolled
Drug / intervention
Memantine +1 moredrug
Likely dose
Memantine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03860597
NCT03860597Phase 4Completed
CompareCT.gov

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

University of California, San Diego·interventional·Posted Mar 4, 2019·Updated Dec 21, 2022

In Brief

A Phase 4 clinical trial evaluating Memantine and Placebos for Schizophrenia and 3 related conditions. Completed, enrolled 42 participants across 1 site.

Detailed Summary

This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedMar 4, 2019
Enrollment StartApr 1, 2018
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 7.3 years ago

Interventions

Memantinedrug

To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.

Placebosdrug

To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.